logoAiPathly

Inari Medical

I

Overview

Inari Medical is a pioneering medical device company dedicated to treating and transforming the lives of patients suffering from venous diseases, with a particular focus on venous thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Mission and Products

The company's mission centers on improving patient outcomes through innovative devices. Their product portfolio includes:

  • FlowTriever System: A large bore catheter-based aspiration and mechanical thrombectomy system for removing large clots from venous vessels, the right heart, pulmonary arteries, and lungs. FDA-approved for Pulmonary Embolism (PE) treatment in 2018 and Right Atrial Clot in Transit in 2021.
  • ClotTriever System: Designed to core, capture, and remove large clots from large venous vessels. Received FDA 510(k) market clearance in 2017 for non-surgical removal of thrombi and emboli from peripheral vasculature.

Clinical Research and Market Presence

Inari Medical demonstrates a strong commitment to clinical data generation through studies and registries such as FLARE, CLOUT, FLASH, FLAME, and PEERLESS. The company operates in multiple countries, including the US, Switzerland, Singapore, Canada, Australia, Brazil, the UK, and Ireland, with a rapidly expanding sales team. The estimated addressable market in the US alone is $5.8 billion, with significant international opportunities.

Financial Performance and Recent Developments

Since its successful IPO in May 2020, Inari Medical has shown robust quarterly revenue growth with gross margins exceeding 80%. Recent developments include:

  • Securing national reimbursement approval in Japan for the ClotTriever Thrombectomy System (December 2024)
  • Entering a joint venture to introduce devices in Greater China
  • Partnering with the American Venous Forum and the National Blood Clot Alliance on the DEFIANCE trial

Commitment to Healthcare

Inari Medical is dedicated to establishing its treatments as the standard of care for VTE and related conditions through innovative solutions, education, clinical research, and program development. Their ethos, "Patients first. Always," underscores their commitment to improving patient outcomes and transforming lives affected by venous diseases.

Leadership Team

Inari Medical's leadership team comprises experienced professionals driving the company's mission to revolutionize venous disease treatment. Key members include:

Executive Leadership

  • Drew Hykes - Chief Executive Officer (CEO): Assumed the role in January 2023, bringing extensive experience from previous positions at Inari Medical, Medtronic, Sequent Medical, and Terumo.

Financial and Operational Leadership

  • Kevin Strange - Chief Financial Officer: Joined in 2020, progressing from VP of Strategy and Business Development to CFO in 2024.
  • Amna Vugdalic - Vice President, Finance

Clinical and Medical Affairs

  • Thomas Tu - Chief Medical Officer: Oversees medical affairs and clinical initiatives.
  • Dr. Andrew Niekamp - Vice President of Medical Affairs: Joined in 2024, bringing expertise in Vascular Interventional Radiology and clinical research.
  • Vic Tapson - Vice President, Medical Affairs

Marketing and Commercial Operations

  • Eric Khairy - Senior Vice President, Marketing: Leads marketing strategies and commercial operations.
  • Tim Benner - Senior Vice President of U.S. Sales: Joined in 2024 with extensive commercial leadership experience.

Product and Business Unit Leadership

  • Tara Dunn - Senior Vice President & General Manager, LimFlow: Oversees the LimFlow business unit.
  • Shon Chakrabarti, MD MPH - Chief Medical Officer, LimFlow: Focuses on improving outcomes for Chronic Limb Threatening Ischemia (CLTI) patients.

Operations and Strategy

  • Paul Koehn - Senior Vice President, Operations: Responsible for operational efficiency.
  • Shawn Flaherty - Vice President US Strategy & Sales

Quality, Regulatory, and Clinical Affairs

  • Mazi Kiani - Joined in 2024 with over two decades of experience in Quality, Regulatory, and Clinical Affairs.
  • Shannon Trevino - General Counsel and Corporate Secretary: Joined in 2023 with over 15 years of legal experience.

Investor Relations

  • Neil Bhalodkar - Joined in 2024 with extensive experience in investor relations and corporate finance. This diverse leadership team combines expertise in medical devices, finance, clinical research, marketing, and operations to drive Inari Medical's growth and innovation in venous disease treatment.

History

Inari Medical, a pioneering medical device company focused on treating venous diseases, has a compelling history marked by innovation and rapid growth. Key milestones include:

Founding and Early Years

  • Founded in 2013 as a spin-out of Inceptus Medical, a medical device incubator
  • Backed by notable investors including Gilde Healthcare, Versant Ventures, and U.S. Venture Partners

Product Development and FDA Approvals

  • Developed two primary mechanical thrombectomy platforms:
    1. FlowTriever System:
      • FDA approval for Pulmonary Embolism (PE) treatment in May 2018
      • Additional clearance for Right Atrial Clot in Transit in January 2021
    2. ClotTriever System:
      • FDA 510(k) market clearance in February 2017 for non-surgical removal of thrombi and emboli from peripheral vasculature

Market Expansion and Growth

  • Completed Initial Public Offering (IPO) in May 2020, raising $156 million
    • Notable as the first non-biotech IPO post-COVID-19 outbreak
    • Shares performed exceptionally well, closing at $42.51 on the first day of trading
  • Expanded commercial organization in the U.S. and internationally
  • Estimated addressable market of $5.8 billion in the U.S. alone, with significant international opportunities

Clinical Research and Studies

  • Invested heavily in clinical research, including studies and registries such as FLARE, CLOUT, FLASH, FLAME, and PEERLESS
  • Focused on generating real-world evidence to drive device adoption and improve patient outcomes

Recent Developments

  • Secured national reimbursement approval in Japan for the ClotTriever Thrombectomy System (December 2024)
  • Entered joint venture agreement to introduce devices in Greater China (December 2024)
  • Partnered with American Venous Forum and National Blood Clot Alliance on the DEFIANCE trial

Mission and Culture

  • Committed to treating and transforming lives of patients with venous diseases
  • Emphasizes patient-first approach, innovation, and a culture valuing diversity and inclusivity Inari Medical has established itself as a leader in venous thromboembolism treatment, driven by innovative products, robust clinical research, and a steadfast commitment to patient care.

Products & Solutions

Inari Medical Inc. specializes in developing innovative catheter-based technologies for treating venous thromboembolism (VTE). Their key products include:

ClotTriever System

  • Designed for deep vein thrombosis (DVT) treatment
  • Uses mechanical coring, collection, and retrieval of emboli and thrombi
  • Components include ClotTriever Thrombectomy Catheter and associated sheaths

FlowTriever System

  • Treats pulmonary embolism (PE) and other vascular thrombi
  • Employs mechanical and aspirational disruption, fragmentation, maceration, and retrieval
  • Includes various catheters: FlowTriever, FlowTriever2, Triever16, Triever20, and Triever24

Artix Thrombectomy System

  • Dual mechanical and aspiration solution for arterial thrombus cases
  • Features covered funnel catheter and MT thrombectomy device
  • Used for nonsurgical removal of emboli and thrombi

Additional Products

  • Protrieve Sheath: Used with Inari's thrombectomy systems
  • InThrill Sheath and Catheter: Part of the thrombectomy portfolio
  • FlowStasis Suture Retention Device: For suture retention
  • FlowSaver Blood Return System: Enables autologous blood transfusion

Clinical Application

Inari Medical's products are utilized by interventional radiologists, cardiologists, and vascular surgeons in catheterization laboratories and interventional suites for treating conditions like DVT and PE.

Core Technology

Inari Medical's core technology focuses on innovative solutions for venous thromboembolism (VTE) and other venous diseases. Key aspects include:

Mechanical Thrombectomy Devices

  1. FlowTriever System
    • First FDA-cleared mechanical thrombectomy device for pulmonary embolism (PE)
    • Enables single-session, thrombolytic-free removal of thrombi from pulmonary arteries
    • Improves patient hemodynamics without thrombolytic-associated risks
  2. ClotTriever System
    • Treats deep vein thrombosis (DVT)
    • Features atraumatic nitinol coring element and mesh collection bag
    • Extracts large thrombi in a single session without thrombolytics or ICU monitoring
  3. RevCore Thrombectomy Catheter
    • Specifically designed for venous in-stent thrombosis
    • Unique diameter-controlled coring element for safe thrombi engagement within stents
  4. Triever16 Curve Catheter
    • Versatile for both PE and peripheral thrombectomy
    • Pre-shaped curve for targeted aspiration
    • Compatible with FlowSaver blood return system

Key Technologies and Features

  • HyperClear Technology: Reduces clot adhesion in collection bags
  • Nitinol Coring Element and Mesh Collection Bag: Facilitates thrombi removal
  • Self-Expanding Nitinol Funnel: Ensures optimal clot extraction

Clinical Performance

  • High rates of thrombus removal
  • Minimal blood loss
  • Improved patient quality-of-life measures
  • CLOUT registry: 100% thrombus removal in most patients, near-complete removal in 85.2% Inari Medical's technologies aim to provide safe, efficient, and effective VTE treatments, often in a single session without thrombolytics, potentially reducing complications and improving outcomes.

Industry Peers

Inari Medical operates in the medical device industry, specializing in venous and related diseases treatment. Key industry peers and competitors include:

Direct Competitors

  1. Retriever Medical
    • Focus: Vascular disease treatment
    • Products: Aspiration catheters, mechanical thrombectomy devices, blood filtration systems
  2. Ceretrieve Ltd.
    • Specialization: Neurointerventional devices
    • Offerings: Distal access catheters, thrombectomy devices
  3. Imperative Care
    • Focus: Stroke and vascular diseases
    • Solutions: Interventional tools, robotic technologies for thrombectomy
  4. Route 92 Medical
    • Specialization: Neurovascular intervention
    • Key Product: FreeClimb catheter systems

Broader Industry Peers

  1. Penumbra: Neuro and vascular healthcare technologies
  2. Teleflex: Global provider of critical care and surgical medical devices
  3. AngioDynamics: Vascular and oncology medical devices
  4. LeMaitre Vascular: Peripheral vascular disease and cardiovascular disease solutions

Publicly Traded Peers

  1. Boston Scientific Corporation: Wide range of medical devices
  2. LivaNova PLC: Cardiovascular and neuromodulation solutions
  3. iRhythm Technologies, Inc.: Cardiac arrhythmia diagnostic and monitoring devices
  4. QuidelOrtho Corporation: Diagnostic and medical device development and manufacturing These companies operate within the broader medical device and healthcare equipment industry, often targeting similar or adjacent markets to Inari Medical.

More Companies

S

Stoke Space

Stoke Space Technologies is an American space launch company founded in 2019, based in Kent, Washington. The company is developing a fully reusable medium-lift launch vehicle called Nova, aiming to revolutionize space access through innovative rocket design and rapid reusability. Key aspects of Stoke Space Technologies include: 1. Founding and Team: Established by former Blue Origin and SpaceX employees, with Andy Lapsa serving as CEO and co-founder. 2. Funding: Secured substantial investments totaling $176.27 million, including grants and venture capital funding rounds. 3. Technology: Developing the Nova rocket, a two-stage vertical takeoff and vertical landing (VTOVL) vehicle: - First Stage: Uses liquid methane fuel and full flow staged combustion cycle engines. - Second Stage: Powered by a hydrolox engine with 30 thrust chambers and a regeneratively cooled heat shield. 4. Facilities: Operates a 168,000 square foot assembly facility in Kent, Washington, and a 75-acre rocket test facility near Moses Lake. 5. Testing and Development: Conducted successful tests including static fires, a Wet Dress Rehearsal, and a 10-meter 'hop' test of the second stage prototype. 6. Future Plans: Targeting an orbital test flight for the Nova rocket, with plans to use Launch Complex 14 in Florida and participation in the Space Force's Orbital Services Program. 7. Innovations: Utilizes stainless steel for rocket structure and implements a center passive bleed in the second stage for improved efficiency. Stoke Space aims to achieve full and rapid reusability with the Nova rocket, which is expected to have a payload capacity of 5 tons to low Earth orbit (LEO). The company's focus on innovation and reusability positions it as a potential disruptor in the space launch industry.

W

Wayve

Wayve is a UK-based technology company at the forefront of developing autonomous vehicle (AV) technology using advanced artificial intelligence and machine learning techniques. ### Founding and Headquarters Founded in 2017 by a team from Cambridge University's Engineering Department, Wayve is headquartered in London, with additional presence in other UK cities and recent expansion to San Francisco, USA. ### Mission and Technology Wayve's mission is to revolutionize autonomous vehicles through cutting-edge machine learning and AI. They pioneer an end-to-end deep learning approach, allowing AVs to adapt to new environments without extensive pre-programming. This 'AV 2.0' approach uses large, unified AI models for perception, planning, and control. ### Key Innovations 1. **End-to-End Learning**: A single large model learns all driving tasks simultaneously, enhancing adaptability. 2. **Generative AI**: Models like GAIA-1 and LINGO-2 create synthetic data and simulate novel driving scenarios. 3. **Embodied AI**: Integration of advanced AI into vehicles to enhance response to human behavior and environmental interactions. ### Funding and Partnerships Wayve has secured significant funding, including a recent $1 billion investment round. They have partnerships with major companies like Uber, Asda, and Ocado, and are part of the NVIDIA Inception program. ### Team and Culture The company comprises a global team of experts in machine learning and robotics. Wayve values autonomy, innovation, collaboration, diversity & inclusion, and continuous learning. ### Expansion and Challenges Wayve is expanding testing from the UK to the US, adapting their AI models to drive on the right side of the road. They are using detailed simulations to ensure a smooth transition, confident in their model's adaptability based on successful performance in different UK cities.

G

GitLab

GitLab is a comprehensive DevSecOps platform that streamlines the entire software development lifecycle. Founded in 2011 by Dmitriy Zaporozhets and Valery Sizov, GitLab has evolved into a robust solution used by over 50,000 businesses and more than 100,000 users, including industry giants like IBM, Sony, Goldman Sachs, and NASA. Key Features: 1. Git Repository Management: Web-based Git repository supporting public and private repositories. 2. CI/CD: Built-in pipelines for automated building, testing, and deployment. 3. Issue Tracking and Project Planning: Tools for Agile development methodologies. 4. Container Registry: Management of Docker container images. 5. Security and Compliance: Automatic secret detection, security testing, and compliance tracking. 6. Collaboration Tools: Wikis, documentation, and detailed permissions for merge and push operations. 7. Third-Party Integrations: Support for JIRA, Slack, Jenkins, Kubernetes, and more. Advantages: - Self-Hosted Option: Can be run in on-premises environments. - User-Friendly Interface: Easy to set up and use. - Free Private Repositories: Unlimited for individuals and organizations. - Reliable Uptime: Minimal disruptions to development workflows. - Community Support: Strong community backing with monthly updates. GitLab's DevSecOps platform integrates development, security, and operations teams, helping to improve cycle times, reduce costs, and speed up time to market. It includes AI-powered tools to enhance the development process from ideation to production. Licensing: Initially open-source under the MIT License, GitLab split into Community (CE) and Enterprise (EE) editions in 2013. In 2017, the company announced a return to full open-source licensing under the MIT License. GitLab continues to evolve, offering a powerful toolset that enhances collaboration, streamlines development processes, and provides robust features for managing and securing code repositories.

R

Rebel Foods

Rebel Foods, formerly known as Faasos, is a pioneering company in the food technology industry, specializing in cloud kitchens and virtual restaurants. Founded in 2011 by Jaydeep Barman and Kallol Banerjee, the company is headquartered in Mumbai, India. The company operates on a cloud kitchen model, which involves a network of kitchens dedicated exclusively to food preparation for delivery. This approach minimizes overhead costs associated with traditional restaurants and allows for significant scalability. As of 2023, Rebel Foods operates 325 cloud kitchens in 35 cities across India and an additional 35 kitchens in Indonesia, the UAE, and the UK. Rebel Foods owns and operates several culinary brands, including Faasos, Behrouz Biryani, Oven Story, and Mandarin Oak, offering a diverse range of cuisines. The company generates revenue through the sale of its food brands via popular delivery platforms, leveraging data analytics and consumer feedback to refine its menu offerings. Key activities include marketing, product management, IT maintenance, operations, quality control, logistics, and training. The company s key resources include its brand portfolio, network of cloud kitchens, large workforce (approximately 3,500 employees), high levels of automation, and significant economies of scale. Rebel Foods s value propositions include offering high-quality, affordable food across various cuisines, providing a range of culinary experiences, and ensuring efficient delivery through its tech-driven approach. The company aims to be the world s largest internet restaurant company and the most affordable quick-service restaurant (QSR) chain. In terms of funding, Rebel Foods has raised approximately $545.53 million from various investors, including InnoVen Capital, Alteria Capital, and Stride Ventures. The company has also expanded into traditional dine-in outlets, notably with the launch of Wendy s® restaurants in India, for which it holds the master franchise. Overall, Rebel Foods is at the forefront of the cloud kitchen revolution, combining culinary expertise with advanced technology to deliver a wide range of culinary options to consumers globally.